MedTrace Logo

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

NCT02415413 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-09-10

No results posted yet for this study

Summary

Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood stem cell transplantation.

Approximately 3 months after peripheral blood stem cell transplantation patients will receive consolidation treatment during 2 months.

Subsequently patients will start maintenance treatment during 24 months. Therefore, the total duration of the treatment will be approximately 36 months.

Conditions

  • Smoldering Multiple Myeloma

Interventions

DRUG

carfilzomib

DRUG

Lenalidomide

DRUG

Dexamethasone

DRUG

Melphalan

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Amgen

    collaborator INDUSTRY

  • PETHEMA Foundation

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2018-07-05
Completion
2027-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02415413 on ClinicalTrials.gov